Rodman & Renshaw reissued their buy rating on shares of Capricor Therapeutics Inc (OTCMKTS:CAPR) in a report published on Saturday morning. The firm currently has a $2.15 price target on the biotechnology company’s stock.
Other equities analysts also recently issued reports about the stock. ValuEngine downgraded shares of Capricor Therapeutics from a sell rating to a strong sell rating in a report on Friday, June 2nd. HC Wainwright set a $2.00 price objective on shares of Capricor Therapeutics and gave the stock a buy rating in a report on Tuesday, July 18th. Finally, Zacks Investment Research raised shares of Capricor Therapeutics from a hold rating to a buy rating and set a $3.50 price objective on the stock in a report on Monday, April 17th. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. The stock currently has a consensus rating of Hold and an average target price of $4.91.
Capricor Therapeutics (OTCMKTS:CAPR) opened at 1.12 on Friday. The firm’s market cap is $25.31 million. The stock has a 50 day moving average of $0.82 and a 200 day moving average of $2.14. Capricor Therapeutics has a 12-month low of $0.63 and a 12-month high of $4.13.
Capricor Therapeutics (OTCMKTS:CAPR) last posted its quarterly earnings data on Monday, May 15th. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.15) by $0.02. The business had revenue of $0.88 million for the quarter, compared to analysts’ expectations of $0.87 million. On average, equities research analysts anticipate that Capricor Therapeutics will post ($0.74) EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Capricor Therapeutics’ (CAPR) “Buy” Rating Reiterated at Rodman & Renshaw” was first posted by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this news story on another domain, it was stolen and reposted in violation of US & international trademark & copyright law. The original version of this news story can be accessed at https://stocknewstimes.com/2017/07/25/capricor-therapeutics-capr-buy-rating-reiterated-at-rodman-renshaw.html.
In other news, Director Louis Manzo acquired 10,000 shares of the stock in a transaction that occurred on Tuesday, May 9th. The shares were acquired at an average cost of $3.10 per share, for a total transaction of $31,000.00. Following the purchase, the director now owns 138,384 shares of the company’s stock, valued at approximately $428,990.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Sinai Medical Center Cedars acquired 1,145,161 shares of the stock in a transaction that occurred on Tuesday, May 9th. The stock was purchased at an average price of $3.10 per share, for a total transaction of $3,549,999.10. Following the completion of the purchase, the insider now directly owns 4,049,959 shares in the company, valued at approximately $12,554,872.90. The disclosure for this purchase can be found here.
Capricor Therapeutics Company Profile
Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapeutics. The Company focuses on discovering, developing and commercializing regenerative medicine and large molecule products for the treatment of disease, with a primary focus on the treatment of cardiovascular diseases, including orphan indications.
Receive News & Ratings for Capricor Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.
